Clinical Outcomes after Triple Vessel Angioplasty in Diabetic Patients with Triple Vessel Coronary Artery Disease

Manzil: Clinical Outcomes after Triple Vessel Angioplasty in Diabetic Patients with Triple Vessel Coronary Artery Disease

Authors

INTRODUCTION

Globally, the prevalence of diabetes mellitus has been escalating since decades in affecting millions of people.1 Diabetes poses to be a risk factor for cardiovascular disease, contributing to higher rates of myocardial infarction and cardiovascular mortality.2,3 Coexistence of diabetes and coronary artery disease (CAD) has been associated with increased mortality and morbidity, because diabetic patients have allied with larger burden of atherogenic risk factors, like hypertension, obesity, dyslipidemia, insulin resistance, elevated levels of plasma fibrinogen,4 enhanced platelet reactivity and reduced responsiveness to antiplatelet agents.5,6 Moreover, literature suggests that diabetics have smaller coronary vessel diameter, diffused lesions, and probably a dissimilar restenotic cascade than nondiabetic patients, thus being highly liable to atherosclerosis and having a greater requirement for undergoing repeat revascularizations,7,8,9 thus leading to poor prognosis in such patients.3,4,5,6,7,8,9,10

Optimal approach for treating multivessel coronary disease has been controversial11 and triple vessel stenosis in diabetic patients make the matter worse. Though coronary artery bypass surgery (CABG) had been the conventional treatment for triple vessel disease,12,13,14 due to presence of some limitations like angiographic features related to the extent, location, and nature of CAD, as well as geographic, demographic and clinical factors; preference of approach shifts to percutaneous coronary intervention (PCI) instead of CABG.15 In addition, some patients have been poor candidates for CABG, like those with disease in distal vessel, severe systemic illness, severe left ventricular dysfunction and previous bypass surgeries.16

The dispute on consideration of PCI or CABG had been ongoing, but the advent of DES has been promising since it has exhibited reduction in restenosis rates in diabetic patients.17,18 Thus, in this study we intended to evaluate clinical outcomes in diabetic patients who underwent triple vessel angioplasty for treatment of triple vessel coronary artery disease.

MATERIALS AND METHODS

This was an observational, single centred study, which included a total of 27 diabetic patients who underwent triple vessel angioplasty at a tertiary care hospital from May 2010 to July 2012. Patients with presence of ≥ 50% stenosis in each of the three major vessels i.e., the left anterior descending artery (LAD), the left circumflex artery (LCX) and the right coronary artery (RCA) and angiographically determined lesions suitable for angioplasty were included in the study.

The patients were excluded if they had multiple chronic total occlusions (CTO) and severe diffuse disease, wherein surgery was considered to offer a more complete revascularisation at a lower risk or if they refused to give consent for follow-up and data release.

Details pertaining to the patient’s history prior to revascularisation, the coronary risk factors, left ventricular function (LVF), and severity of the lesions and details of the procedure were taken from the hospital records. These patients were followed-up to reassess their functional status and LVF by history, electrocardiogram, and echocardiogram and treadmill test. Any case of mortality was considered to be due to cardiac cause and hence a procedural failure if there was no other obvious cause like accidents. Mortality and morbidity were considered as end-points of the study.

Statistical analysis: Continuous variables were presented as mean ± standard deviation (SD) and categorical variables as counts and percentages. All data were analysed using the Statistical Package for Social Sciences (SPSS; Chicago, IL, USA) program, version 15.

RESULTS

Of 27 patients who underwent triple vessel angioplasty, 18 were males and mean age of patients was 55 years. About 55.6% (n = 15) patients were hypertensives and 33.3% had hypercholesterolemia. Majority of patients had ST-elevation myocardial infarction (STEMI) (40.7%; n=11). Normal LVF (EF>60%) was observed in 70.4% of patients. Table 1 outlines demographic characteristics of patients. All patients had flow limiting stenosis of the RCA, LAD, and LCX. Total 81.5% (n =22/27) patients underwent PCI with stenting to all the three major vessels but the rest 5 (18.5%) patients had PCI with stenting in two vessels and plain old balloon angioplasty (POBA) in one. The mean SYNTAX score was 17.5 (range 9 to 29). The average number of lesions per patient was 3.6 and total number of stents were 85 (Table 2). The percentage of lesions successfully treated by angioplasty were 94.8% (n =92/97). A drug eluting stent was implanted in 94.1% (n = 80/85) of instances and the rest were bare metal stents (n = 5/85). Baseline angioplasty results are outlined in Table 3.

The average time of follow-up was 20.3 months. Twenty-five (92.6%) patients had improved symptomatically or were event free. Table 4 details clinical outcomes of the patients at follow-up. Two patients (7.4%) had clinical recurrence. Two patient developed recurrent, event-free angina after 13 and 27 months of the procedure. Two patients who survived following clinical recurrence were managed medically and are at present symptom free. Thus, there was a 100% continued success with triple vessel angioplasty in diabetic patients in our study.

DISCUSSION

In various studies, PCI has demonstrated favourable outcomes in patients with multivessel CAD.19,20,21,22 However, the amalgamation of multivessel disease with diabetes fans the flames, leading to wrangle on selection of appropriate treatment modality. In this study, the diabetic patients with triple vessel coronary artery disease underwent PCI with either bare metal stents or drug eluting stents, or underwent balloon angioplasty and were followed up clinically. Of 27 patients, 18 were males, and 55.6% were hypertensive. Total number lesions were 97 and the total stents implanted were 85. At an average follow-up of 20.3 months, 25 patients were event free or improved symptomatically, while 2 patients experienced angina and were managed medically. There was no mortality during this follow-up period. There have been many studies that have compared the outcomes in diabetic patients after CABG and PCI.23,24 Most of these studies did not indicate a compromise in survival of diabetic patients after DES implantation; stating equivalence in mortality rates among diabetic patients with multivessel disease who underwent CABG or PCI with either BMS or DES.25,26,27,28,29 Moreover, ARTS-II trial, at 3-year follow-up, demonstrated lower death/cerebrovascular events/MI rates in diabetic patients treated with sirolimus-eluting stents (9.4%) than those treated with CABG (13.5%) or BMS (18.8%).18 Literature suggests that diabetes has been an independent risk factor for development of stroke in patients undergoing CABG.30 In accordance to this, various studies also favour PCI with DES over CABG in terms of occurrence of cerebrovascular events in such patients (OR [95%CI] = 2.15[0.99–4.68]).24 Additionally, a prospective study has reported that 42% of patients who underwent CABG have subtle cognitive impairment 5 years after surgery.31 On contrary, many studies reveal favour towards CABG than PCI in diabetic patients with multivessel disease in terms of repeat revascularisation (OR [95%CI] = 0.30 [0.25, 0.36]), probably occurring due to diffused lesions and more vulnerable plaque in such patients.23

Table 1

Baseline Characteristics of Patients

CharacteristicsN = 27 patients
Age (mean ± SD, yrs)55 ± 10
Male, n (%)18 (66.7%)
Cardiovascular risk
Diabetes mellitus, n (%)27 (100%)
Hypertension, n (%)15 (55.6%)
Hypercholesterolemia, n (%)9 (33.3%)
Smoking or tobacco use, n (%)4 (14.8%)
Family history of CAD, n (%)5 (18.5%)
Cerebrovascular accident, n (%)1 (3.7%)
Clinical presentation
Stable angina, n (%)3 (11.1%)
Unstable angina, n (%)6 (22.2%)
ST-elevated myocardial infarction, n (%)11 (40.7%)
Non ST-elevated myocardial infarction, n (%)6 (22.2%)
Silent ischemia, n (%)1 (3.7%)
NYHA class
Class II, n (%)2 (7.4%)
Class III, n (%)8 (29.6%)
Class IV, n (%)17 (63.0%)
LV Systolic Function
Normal, n (%)19 (70.4%)
Borderline, n (%)2 (7.4%)
Mild dysfunction, n (%)3 (11.1%)
Moderate dysfunction, n (%)3 (11.1%)

However, on the bright side, PCI presents perceptible advantages of lack of operative complications like repeat thoracotomy for bleeding, postoperative pneumonia, permanent pacemaker implantation, pleural effusions, renal failure requiring hemodialysis, atrial fibrillation, and ventricular tachycardia or ventricular fibrillation, which affects more than 50% of diabetic patients who underwent CABG.32 Nevertheless, the comparisons between applicability of PCI and CABG in diabetic patients have been majorly limited by the subgroup analysis of larger trials, leading to underpowered results.1 The choice of revascularisation in diabetic patients with triple vessel disease involves a multidisciplinary approach with cardiologists and cardiac surgeons.24 The decision regarding the type of treatment modality must be individualised based on patient’s clinical condition, pertaining to various criteria like patient demographics, extent of myocardial jeopardy, anatomy of lesion and vessel, and angiographic findings. Thus, the apt selection of treatment strategy increases the favourability of outcomes in such patients.

Table 2

Lesion Characteristics of Patients

CharacteristicsPatients = 27 / Lesions = 97
Lesion location
Left anterior descending, n (%)27 (100%)
Right coronary artery, n (%)27 (100%)
Left circumflex, n (%)27 (100%)
Left main, n (%)1 (3.7%)
Ramus intermedius, n (%)1 (3.7%)
Syntax score, (mean (range))17.5 (9-29)
Total no. of stents85
Average stent length, (mean ± SD, mm)24.9 ± 7.9
Average stent diameter, (mean ± SD, mm)3.0 ± 0.4
Table 3

Baseline Results of Angioplasty

No. of lesionsNo. of patientsTotal no. of lesionsNo. of angioplasties attempted successfully
3154545
483230
542017
Total279792 (94.8%)
Table 4

Clinical Outcomes after Successful Angioplasty

VariablesN = 27 patients
Mean follow-up (mean ± SD, months)20.3 ± 7.0
Event-free, improved, n (%)25 (92.6%)
Clinical recurrence, n (%)2 (7.4%)
Medical therapy, improved, n (%)1 (3.7%)
Death, n (%)0 (0.0%)
Continued success, n (%)27 (100%)

Study limitations

The study suffers a limitation of small sample size and of being a single arm study without a comparator group.

CONCLUSION

Triple vessel angioplasty can be applied as favourable therapy as an alternative to surgical revascularization in selected diabetic patients. However, larger studies with long-term follow-up would warrant the effectiveness of triple vessel angioplasty in such patients.

Notes

[1] Conflicts of interest CONFLICTING INTEREST None

ABBREVIATION USED

CAD

Coronary artery disease

CABG

Coronary artery bypass surgery

PCI

Percutaneous coronary intervention

LAD

Left anterior descending artery

LCX

Left circumflex artery

RCA

Right coronary artery

CTO

Chronic total occlusions

LVF

Left ventricular function

SD

Standard deviation

STEMI

ST-elevation myocardial infarction

POBA

Plain old balloon angioplasty

REFERENCES

1. 

Kappetein AP, Head SJ, Morice M-C, Banning AP, Serruys PW, Mohr F-W, et al. , authors. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. European Journal of Cardio-Thoracic Surgery. 2013;43(5):1006–13

2. 

Jacoby RM, Nesto RW , authors. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. Journal of the American College of Cardiology. 1992;20(3):736–44

3. 

Kip K, Faxon D, Detre K, Yeh W, Kelsey S, Currier J , authors; for the investigators of the NHLBI PTCA registry. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1996;94(8):1818–25

4. 

Mukesh Singh M, Rohit Arora M, Vamsi Kodumuri M, Sandeep Khosla M, Evyan Jawad M , authors. Coronary revascularization in diabetic patients: current state of evidence. clin cardiol. 2011;16(1):16–22

5. 

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, et al. , authors. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54(8):2430–5

6. 

Angiolillo DJ, Bernardo E, Ramírez C, Costa MA, Sabaté M, Jimenez-Quevedo P, et al. , authors. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. Journal of the American College of Cardiology. 2006;48(2):298–304

7. 

West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O’Neill WW, et al. , authors. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation. 2004;109:867–73

8. 

Niles NW, McGrath PD, Malenka D, Quinton H, Wennberg D, Shubrooks SJ, et al. , authors. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Journal of the American College of Cardiology. 2001;37(4):1008–15

9. 

Lincoff AM , author. Important triad in Cardiovascular Medicine. Circulation. 2003;107(11):1556–9

10. 

Stein B, Weintraub WS, Gebhart SS, Cohen-Bernstein CL, Grosswald R, Liberman HA, et al. , authors. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91(4):979–89

11. 

Panchal K, Patel S, Bhatt P , authors. Drug-eluting stents in multivessel coronary artery disease: cost Effectiveness and clinical outcomes. Advances in pharmacological sciences. 2012;

12. 

Hoffman SN, TenBrook JA, Wolf MP, Wong JB, Pauker SG, Salem DN , authors. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one-to eight-year outcomes. Journal of the American College of Cardiology. 2003;41:1293–304

13. 

Buszman PE, Buszman PP, Bochenek A, Gierlotka M, Gąsior M, Milewski K, et al. , authors. Comparison of Stenting and Surgical Revascularization Strategy in Non-ST Elevation Acute Coronary Syndromes and Complex Coronary Artery Disease (from the Milestone Registry). The American journal of cardiology. 2014;114(7):979–87

14. 

van den Brand MJ, Rensing BJ, Marie-angèle MM, Foley DP, de Valk V, Breeman A, et al. , authors. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. Journal of the American College of Cardiology. 2002;39(4):559–64

15. 

Kim LJ, King SB, Kent K, Brooks MM, Kip KE, Abbott JD, et al. , authors. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. JACC: Cardiovascular Interventions. 2009;2(5):384–92

16. 

DiSciascio G, Cowley MJ, Vetrovec GW, Kelly KM, Lewis SA , authors. Triple vessel coronary angioplasty: Acute outcome and long-term results. Journal of the American College of Cardiology. 1988;12(1):42–8

17. 

Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, et al. , authors. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. Bmj. 2008;337:a1331

18. 

Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, et al. , authors. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study–Part II) Trial. Journal of the American College of Cardiology. 2008;52(24):1957–67

19. 

Chandwani P, Verma P, Saxena S, K Ramachandran P, Abhyankar A, S Sandhu M, et al. , authors. Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents). 2016;14(1):39–48

20. 

Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, et al. , authors. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (Executive RCT: evaluating XIENCE V in a multi vessel disease). JACC: Cardiovascular Interventions. 2013;6(10):1012–22

21. 

From AM, Al Badarin FJ, Cha SS, Rihal CS , authors. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis of data from the ARTS II, CARDia, ERACI III, and SYNTAX studies and systematic review of observational data. EuroIntervention. 2010;6(2):269–76

22. 

Polavarapu A, Polavarapu RS, Prajapati J, Raheem A, Mayall T, Thakkar A , authors. Clinical performance of biodegradable polymer coated Sirolimus-eluting stent in multivessel disease: Results from MULTIDES study. Heart India. 2016;4(1):5

23. 

De Luca G, Schaffer A, Verdoia M, Suryapranata H , authors. Meta-analysis of 14 trials comparing bypass grafting vs drug-eluting stents in diabetic patients with multivessel coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases. 2014;24(4):344–54

24. 

Lee MS, Yang T, Dhoot J, Iqbal Z, Liao H , authors. Meta-analysis of studies comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease. The American journal of cardiology. 2010;105(11):1540–4

25. 

Banning AP, Westaby S, Morice M-C, Kappetein AP, Mohr FW, Berti S, et al. , authors. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. Journal of the American College of Cardiology. 2010;55(11):1067–75

26. 

King SB, Lembo NJ, Weintraub WS, Kosinski AS, Barnhart HX, Kutner MH, et al. , authors. A randomized trial comparing coronary angioplasty with coronary bypass surgery. New England Journal of Medicine. 1994;331(16):1044–50

27. 

Macaya C, Garcia-Garcia HM, Colombo A, Morice M-C, Legrand V, Kuck K-H, et al. , authors. One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease. Sirolimus stent vs. coronary artery bypass surgery and bare metal stent: insights from ARTS-II and ARTS-I. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2006;2(1):69–76

28. 

Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, et al. , authors. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. Journal of the American College of Cardiology. 2010;55(5):432–40

29. 

Serruys PW, Morice M-C, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. , authors. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New England Journal of Medicine. 2009;360(10):961–72

30. 

Antunes PE, de Oliveira JF, Antunes MJ , authors. Coronary surgery in patients with diabetes mellitus: a risk-adjusted study on early outcome. European Journal of Cardio-Thoracic Surgery. 2008;34(2):370–5

31. 

Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, et al. , authors. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. New England Journal of Medicine. 2001;344(6):395–402

32. 

Lee MS, Jamal F, Kedia G, Chang G, Kapoor N, Forrester J, et al. , authors. Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. International journal of cardiology. 2007;123(1):34–42